

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

10 Jun 2026

### Clinical trial of the effect of topical tranexamic acid on the amount of episiotomy bleeding in primigravida women and comparison with the control group

#### Protocol summary

##### Study aim

In relation to postpartum bleeding, extensive studies have been conducted on the positive effect of tranexamic acid in reducing post-partum bleeding, its administration time, and effective dose, but its local effect on episiotomy bleeding in vaginal deliveries has not been investigated and the purpose of this study is to investigate this issue.

##### Design

A clinical trial with a control group, with parallel groups, one-sided blind, randomized, 162 patients. The software was used for randomization.

##### Settings and conduct

place: Akbarabadi hospital maternity ward Immediately after the removal of the placenta, Trenexamic or normal saline solution will be poured locally on the episiotomy site. Take the solution freely without the interference of sterile gas and similar We pour it on the site and wait for a minute (the medicine is not injected on the site. The patient and the analyzer are blind.

##### Participants/Inclusion and exclusion criteria

Inclusion criteria: All vaginal births over 34 weeks in primiparous women who are candidates for episiotomy  
exclusion criteria: Lack of consent to participate in the study  
Patients with known coagulopathy  
History of previous perineal surgery  
Patients with uterine atony  
retained placenta  
Instrumental delivery  
Simultaneous rupture of the cervix  
Receiving venous tranexamic acid

##### Intervention groups

In the intervention group, 1 gram of Trenoxamic acid with 20 cc of normal saline is poured at the episiotomy site. In the control group, 20 cc of normal saline is poured into the episiotomy site.

##### Main outcome variables

Hemoglobin and hematocrit changes, the need to receive blood, the duration of hospitalization, the rate of wound opening and the rate of wound infection, and the rate of

thromboembolic events.

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20180409039247N4**

Registration date: **2023-02-23, 1401/12/04**

Registration timing: **prospective**

Last update: **2023-02-23, 1401/12/04**

Update count: **0**

##### Registration date

2023-02-23, 1401/12/04

##### Registrant information

##### Name

Marjan Ghaemibidgoli

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 21 8800 4858

##### Email address

m\_ghaemi@razi.tums.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2023-04-05, 1402/01/16

##### Expected recruitment end date

2023-10-08, 1402/07/16

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

**Trial completion date**

empty

**Scientific title**

Clinical trial of the effect of topical tranexamic acid on the amount of episiotomy bleeding in primigravida women and comparison with the control group

**Public title**

The effect of topical tranexamic acid on the episiotomy bleeding, a clinical trial

**Purpose**

Prevention

**Inclusion/Exclusion criteria****Inclusion criteria:**

vagina delivery beyond 34 weeks primiparity candidates for episiotomy

**Exclusion criteria:**

Lack of consent to participate in the study known coagulopathy history of previous perineal surgery uterine atony retained placenta delivery with instruments Cervical rupture at the same time receiving spontaneous tranexamic acid

**Age**

From **18 years** old to **45 years** old

**Gender**

Female

**Phase**

N/A

**Groups that have been masked**

- Participant
- Data analyser

**Sample size**

Target sample size: **162**

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

A computerized randomization list, generated by an independent statistician blinded to the trial and unrelated to the subjects involved, will use 1:1 allocation. All participants are blinded to the list. The randomization list will be administered using identical, sequentially numbered containers of study medication. These containers will be labeled identically by two investigators who will not be involved in recruiting study subjects. The block random allocation method was designed by an epidemiologist using WWW.Sealedenvelop.com. The blocks will be 2 alleles of size 6. The random assignment list is AAABBB-AABBAB-ABBBAA-AABABB-...., in this sequence A is transgenic and B is controlled.

**Blinding (investigator's opinion)**

Single blinded

**Blinding description**

A single blind study in which the patient and the analyst are blinded. In the consent form, the patient is aware of the two study groups, but does not know whether he is in the intervention group or the control group. The researcher is not blind because he supervises the episiotomy process and uses the medicine. The nurse is not blind because the doctor prescribes the medicine. The information in the forms and the evaluation table are

marked with codes that the analyst is blind to and does not know the type of division.

**Placebo**

Not used

**Assignment**

Single

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Iran university of Medical Sciences

**Street address**

Iran University of Medical Sciences, Hemat Highway, next to Milad Tower, Tehran

**City**

Tehran

**Province**

Tehran

**Postal code**

۱۴۴۹۶۱۴۵۳۵

**Approval date**

2023-01-21, 1401/11/01

**Ethics committee reference number**

IR.IUMS.REC.1401.837

**Health conditions studied****1****Description of health condition studied**

Episiotomy bleeding rate

**ICD-10 code**

O72

**ICD-10 code description**

Postpartum hemorrhage

**Primary outcomes****1****Description**

The primary outcomes is changes in hemoglobin and hematocrit, the need for blood transfusion, the duration of hospitalization

**Timepoint**

Hemoglobin and hematocrit check before admission and 12 hours later and also to check complications 1 week after discharge.

**Method of measurement**

Hemoglobin and hematocrit check with blood test (cbc) and check the need for transfusion, discharge time, possible wound opening and thromboembolic events based on history

## Secondary outcomes

empty

## Intervention groups

1

### Description

Tranexamic acid mixed with 20 cc of normal saline pored in episiotomy site.

### Category

Prevention

2

### Description

Control group: 20 cc of normal saline pored in episiotomy site.

### Category

Prevention

## Recruitment centers

1

### Recruitment center

#### Name of recruitment center

Akbarabadi hospital

#### Full name of responsible person

Maliheh Fakehi

#### Street address

Baghefrdos station, Moulavi Street

#### City

Tehran

#### Province

Tehran

#### Postal code

1168743514

#### Phone

+98 21 5560 6034

#### Email

akbarabadihosp@yahoo.com

## Sponsors / Funding sources

1

### Sponsor

#### Name of organization / entity

Iran University of Medical Sciences

#### Full name of responsible person

Maliheh Fakehi

#### Street address

Bagheferdos station, Moulavi Street

#### City

Tehran

#### Province

Tehran

#### Postal code

1168743514

#### Phone

+98 21 5560 6034

#### Email

maryam.fakehi@gmail.com

#### Grant name

#### Grant code / Reference number

#### Is the source of funding the same sponsor organization/entity?

Yes

#### Title of funding source

Iran University of Medical Sciences

#### Proportion provided by this source

100

#### Public or private sector

Public

#### Domestic or foreign origin

Domestic

#### Category of foreign source of funding

empty

#### Country of origin

#### Type of organization providing the funding

Academic

## Person responsible for general inquiries

### Contact

#### Name of organization / entity

Iran University of Medical Sciences

#### Full name of responsible person

Maryam Fakehi

#### Position

Assisted professor

#### Latest degree

Specialist

#### Other areas of specialty/work

Gynecology and Obstetrics

#### Street address

Bagheferdos station, Moulavi Street

#### City

Tehran

#### Province

Tehran

#### Postal code

1168743514

#### Phone

+98 21 5560 6034

#### Email

marjan\_ghaemi@yahoo.com

## Person responsible for scientific inquiries

### Contact

#### Name of organization / entity

Tehran University of Medical Sciences

#### Full name of responsible person

Marjan Ghaemibidgoli

#### Position

Assisted professor

#### Latest degree

Medical doctor

#### Other areas of specialty/work

Gynecology and Obstetrics

**Street address**

Emam khomeini hospital

**City**

Tehran

**Province**

Tehran

**Postal code**

14146

**Phone**

+98 21 8800 4858

**Fax****Email**

marjan\_ghaemi@yahoo.com

**City**

Tehran

**Province**

Tehran

**Postal code**

14146

**Phone**

+98 21 8800 4858

**Fax****Email**

marjan\_ghaemi@yahoo.com

**Sharing plan****Deidentified Individual Participant Data Set (IPD)**

Undecided - It is not yet known if there will be a plan to make this available

**Study Protocol**

No - There is not a plan to make this available

**Statistical Analysis Plan**

No - There is not a plan to make this available

**Informed Consent Form**

No - There is not a plan to make this available

**Clinical Study Report**

No - There is not a plan to make this available

**Analytic Code**

No - There is not a plan to make this available

**Data Dictionary**

No - There is not a plan to make this available

**Person responsible for updating data****Contact****Name of organization / entity**

Tehran University of Medical Sciences

**Full name of responsible person**

Marjan

**Position**

Assisted professor

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Gynecology and Obstetrics

**Street address**

No. 25 Naz Alley, Babataher St